Oxytocin (Synonyms: α-Hypophamine; Oxytocic hormone)

Name: Oxytocin
Brand: MedChemExpress
SKU: HY-17571
Rating: 5.0 (24 reviews)

Cat. No.: HY-17571 Purity: 99.87%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Oxytocin (α-Hypophamine; Oxytocic hormone) is a pleiotropic, hypothalamic peptide known for facilitating parturition, lactation, and prosocial behaviors. Oxytocin can function as a stress-coping molecule with anti-inflammatory, antioxidant, and protective effects especially in the face of adversity or trauma.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

CAS No. : 50-56-6

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
2 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 24 publication(s) in Google Scholar

Other Forms of Oxytocin:

24 Publications Citing Use of MCE Oxytocin

RT-PCR

In Vivo Efficacy Study

Histological Imaging/Staining

: Oxytocin purchased from MedChemExpress. Usage Cited in: Transl Psychiatry. 2024 May 25;14(1):208. [Abstract]; Trajectories of PEL-treated group (n = 6), AVP-supplemented group (n = 6), Oxytocin acetate (administered intraperitoneally 1 mg/kg/d for i.p., 50 ng for hippocampal stereotactic injection)-supplemented group (n = 6), and ATO group (n = 6) in the MWM place navigation experiment.

: Oxytocin purchased from MedChemExpress. Usage Cited in: Transl Psychiatry. 2024 May 25;14(1):208. [Abstract]; Trajectories of PEL-treated group (n = 6), AVP-supplemented group (n = 6), Oxytocin acetate (administered intraperitoneally 1 mg/kg/d for i.p., 50 ng for hippocampal stereotactic injection)-supplemented group (n = 6), and ATO group (n = 6) in the MWM spatial exploration experiment. The shaded part is the area around the platform, and the activity time of mice in the shaded part is calculated.

: Oxytocin purchased from MedChemExpress. Usage Cited in: Transl Psychiatry. 2024 May 25;14(1):208. [Abstract]; Validation of activation of endogenous Oxytocin acetate neurons in mice with PVN Oxytocin acetate neurons activated after PEL surgery.

: Oxytocin purchased from MedChemExpress. Usage Cited in: Psychoneuroendocrinology. 2024 Oct:168:107138. [Abstract]; Expression of OT (Oxytocin) signaling related genes in the hippocampus. RT-PCR analysis were performed on brain tissues from the hippocampus. Con: control; Veh: Vehicle (Saline); RIS: Risperidone; LOT: Low dose (6 μg/kg) of OT; MOT: Medium dose (20 μg/kg) of OT; HOT: High dose (60 μg/kg) of OTAfter 1 week of acclimation, animals in the control group were administered saline (10 ml/kg) and those in the model group were administered MK801 (0.6 mg/kg) through intraperitoneal (i. p.) injections once a day for 21 days. One week after MK801 administration, 6 μg/kg OT (LOT group, n = 10), 20 μg/kg OT (MOT group, n = 10), or 60 μg/kg OT (HOT group, n = 10) was given through the i.n. route twice daily, at 8:30–9:30 AM and 4:00–5:00 PM, for 14 days. Saline (0.2 μL/g) was administered intranasally in the control and vehicle groups. Then, the mice received an i.p. injection of MK801 30 min after OT administration. The mice in the RIS group received an i.p. injection of 0.3 mg/kg RIS once daily for 14 days

: Oxytocin purchased from MedChemExpress. Usage Cited in: Psychoneuroendocrinology. 2024 Oct:168:107138. [Abstract]; Effects of chronic intranasal OT (Oxytocin) on levels of spontaneous activity and anxiety-like behaviors in MK801-induced mice Fig. A, the total distance traveled by the mice in the open field test. Fig. 2B, the ratio of distance traveled in the central versus peripheral zone by the mice in the open field test. Con: control; Veh: Vehicle (Saline); RIS: Risperidone; LOT: Low dose (6 μg/kg) of OT; MOT: Medium dose (20 μg/kg) of OT; HOT: High dose (60 μg/kg) of OTAfter 1 week of acclimation, animals in the control group were administered saline (10 ml/kg) and those in the model group were administered MK801 (0.6 mg/kg) through intraperitoneal (i.p.) injections once a day for 21 days. One week after MK801 administration, 6 μg/kg OT (LOT group, n = 10), 20 μg/kg OT (MOT group, n =10), or 60 μg/kg OT (HOT group, n = 10) was giventhrough the i.n. route twice daily, at 8:30–9:30 AM and 4:00–5:00 PM, for 14 days. Saline (0.2 μL/g) was administered intranasally in the control and vehicle groups. Then, the mice received ani.p. injection of MK801 30 min after OT administration. The mice in the RIS group received an i.p. injection of 0.3 mg/kg RIS once daily for 14 days.

: Oxytocin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Jan 2;8(1):3. [Abstract]; Representative heatmaps showing the duration and location of the shControl and shScgn mice during the 10 min social novelty recognition test. Warmer colors (red) indicate a greater amount of time spent exploring by the mice. shControl: PVN Control-shRNA injection mouse. shScgn: PVN Scgn-shRNA injection mouse. DMSO: 0.1% DMSO administration. Oxytocin acetate: 1 mg/kg Oxytocin administration. S1: a familiar mouse. S2: a novel mouse.

: Oxytocin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Jan 2;8(1):3. [Abstract]; Statistics of marbles burying numbers in shControl and shScgn mice treated with DMSO or Oxytocin acetate.

: Oxytocin purchased from MedChemExpress. Usage Cited in: J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]; Effect of OT on CGRP and c-fos expression levels. A and C show c-fos, B and D show CGRP. Immunofluorescence staining showed that the number of c-fos-positive cells per FOV and the average fluorescence intensity of CGRP were significantly increased in the NTG + vehicle group compared with the sham group. OT administration significantly reduced the expression of CGRP and c-fos, while these effects were prevented after adding L368,899. Repeated OT (Oxytocin, 20 µg/kg) treatments were quickly administered at 2 µL per nostril or the same volume of saline every two minutes using the tip of the pipette 30 min before NTG and then once daily at the same time point for 11 days.C57BL/6 mice weighing 20 ~ 30 g and 6 ~ 8 weeks of age.

: Oxytocin purchased from MedChemExpress. Usage Cited in: J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]; WB data quantification in the mouse trigeminal nucleus caudalis. Repeated OT (Oxytocin, 20 µg/kg) treatments were quickly administered at 2 µL per nostril or the same volume of saline every two minutes using the tip of the pipette 30 min before NTG and then once daily at the same time point for 11 days.C57BL/6 mice weighing 20 ~ 30 g and 6 ~ 8 weeks of age.

: Oxytocin purchased from MedChemExpress. Usage Cited in: J Headache Pain. 2021 Jul 27;22(1):84. [Abstract]; OT ameliorated pain sensitization and reduced neuronal activation via OTR. Note that L-368,899 was intraperitoneally injected daily 1 h before OT treatment. The mechanical and thermal pain thresholds of the hind paw and periorbital area were assessed before each NTG injection and on day 11. B, C, D The basal mechanical pain thresholds of the hind paw (B), periorbital area (C), and the thermal pain response of the hind paw (D) were significantly increased in the NTG + OT group compared with the NTG + vehicle group.The pain threshold in the NTG + OT + L368,899 group was markedly decreased compared with the NTG + OT group.Repeated OT (Oxytocin, 20 µg/kg) treatments were quickly administered at 2 µL per nostril or the same volume of saline every two minutes using the tip of the pipette 30 min before NTG and then once daily at the same time point for 11 days.C57BL/6 mice weighing 20 ~ 30 g and 6 ~ 8 weeks of age.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.04 nM Compound: 1; OT	Agonist activity at human oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 90 sec by fluo-4 dye based FLIPR assay Agonist activity at human oxytocin receptor expressed in CHO cells assessed as increase in intracellular calcium flux measured for 90 sec by fluo-4 dye based FLIPR assay	[PMID: 27297999]
CHO	EC₅₀	10.8 nM Compound: OT	Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay	[PMID: 21428295]
CHO	EC₅₀	24.5 nM Compound: OT	Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay	[PMID: 21428295]
CHO-K1	EC₅₀	2.3 nM Compound: 1, OT	Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
COS-1	EC₅₀	15 nM Compound: 1, OT	Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay	[PMID: 21117646]
HEK293	EC₅₀	0.0046 nM Compound: OT	Agonist activity at human OTR receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at human OTR receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 31229420]
HEK293	EC₅₀	0.01 nM Compound: OT	Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 30896946]
HEK293	EC₅₀	0.18 nM Compound: OT	Agonist activity at human V1A receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at human V1A receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 31229420]
HEK293	EC₅₀	0.19 nM Compound: OT	Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 30896946]
HEK293	EC₅₀	0.2 nM Compound: OT	Agonist activity at human V1B receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at human V1B receptor expressed in HEK293 cells assessed as intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 31229420]
HEK293	EC₅₀	0.24 nM Compound: OT	Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 30896946]
HEK293	EC₅₀	10 nM Compound: 1, OT	Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
HEK293	EC₅₀	2.1 nM Compound: 1; OT	Agonist activity at human oxytocin receptor expressed in HEK293 cells coexpressing Rluc8-tagged Galphaq, N-terminal GFP-tagged Ggamma2 and Gbeta1 protein incubated for 2 mins by Gq protein activation based BRET assay Agonist activity at human oxytocin receptor expressed in HEK293 cells coexpressing Rluc8-tagged Galphaq, N-terminal GFP-tagged Ggamma2 and Gbeta1 protein incubated for 2 mins by Gq protein activation based BRET assay	[PMID: 27420737]
HEK293	EC₅₀	240 nM Compound: 1, OT	Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
HEK293	EC₅₀	5 nM Compound: OT	Agonist activity at wild type OTR (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay Agonist activity at wild type OTR (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay	[PMID: 25642985]
HEK293	EC₅₀	7.3 nM Compound: 1, OT	Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
HEK293	EC₅₀	8 nM Compound: OT	Agonist activity at SNAP-tagged oxytocin receptor (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay Agonist activity at SNAP-tagged oxytocin receptor (unknown origin) expressed in HEK293 cells assessed as intracellular calcium flux after 3 mins by fluorescence assay	[PMID: 25642985]
HEK293	IC₅₀	2.7 nM Compound: I, OT	Displacement of [3H]OT from human OT receptor expressed in HEK cells Displacement of [3H]OT from human OT receptor expressed in HEK cells	[PMID: 17316912]
HEK293	IC₅₀	> 10000 nM Compound: 1, OT	Antagonist activity at human vasopressin V1a expressed in AVP-stimulated HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Antagonist activity at human vasopressin V1a expressed in AVP-stimulated HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]

In Vivo

During the LMA task, rat core body temperature are modestly decreased. Oxytocin (subcutaneous injection; 0.1 mg/kg-0.3 mg/kg; single dose) produces significantly greater hypothermia (at 0.3 mg/kg) than either saline or the two lower doses of oxytocin. Oxytocin at 0.3 mg/kg produces a significantly greater decrease in temperature than vehicle between 15-60 min post injection, whereas 0.1 mg/kg slightly decreases temperature at the 30 min time point only^[1].
Oxytocin (0.1 mg/kg) engages in significantly more body sniffing and ano-genital sniffing compared with saline controls. It also increases the total time spent in social interaction (71.6±4.3 s), compared to those receiving vehicle (56.9±4.1 s)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fifty-six male Lister-hooded rats (150-200 g)^[1]
Dosage:	0.1 mg/kg-0.3 mg/kg
Administration:	Subcutaneous injection; 0.1 mg/kg-0.3 mg/kg; single dose
Result:	Produced significantly greater hypothermia (at 0.3 mg/kg) than the saline group.

Molecular Weight

1007.19

Formula

C₄₃H₆₆N₁₂O₁₂S₂

CAS No.

50-56-6

Appearance

Solid

Color

White to off-white

Sequence

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Disulfide bridge:Cys1-Cys6)

Sequence Shortening

CYIQNCPLG-NH2 (Disulfide bridge:Cys1-Cys6)

Structure Classification

Others

Initial Source

Animals

Endogenous metabolite

the paraventricular and supraoptic nuclei of the hypothalamus

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (99.29 mM)

DMSO : 100 mg/mL (99.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9929 mL	4.9643 mL	9.9286 mL
5 mM	0.1986 mL	0.9929 mL	1.9857 mL
10 mM	0.0993 mL	0.4964 mL	0.9929 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% PBS
Solubility: ≥ 0.5 mg/mL (0.50 mM); Clear solution

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: ≥ 25 mg/mL (24.82 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (287 KB) SDS (480 KB)

COA (266 KB) RP-HPLC (247 KB) LCMS (325 KB) Elemental Analysis Report (125 KB)

Handling Instructions (2659 KB)

References

[1]. Shivali Kohli, et al. Oxytocin attenuates phencyclidine hyperactivity and increases social interaction and nucleus accumben dopamine release in rats. Neuropsychopharmacology. 2019 Jan;44(2):295-305. [Content Brief]

[2]. C Sue Carter, et al. Is Oxytocin "Nature's Medicine"? Pharmacol Rev. 2020 Oct;72(4):829-861. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	0.9929 mL	4.9643 mL	9.9286 mL	24.8215 mL
	5 mM	0.1986 mL	0.9929 mL	1.9857 mL	4.9643 mL
	10 mM	0.0993 mL	0.4964 mL	0.9929 mL	2.4822 mL
	15 mM	0.0662 mL	0.3310 mL	0.6619 mL	1.6548 mL
	20 mM	0.0496 mL	0.2482 mL	0.4964 mL	1.2411 mL
	25 mM	0.0397 mL	0.1986 mL	0.3971 mL	0.9929 mL
	30 mM	0.0331 mL	0.1655 mL	0.3310 mL	0.8274 mL
	40 mM	0.0248 mL	0.1241 mL	0.2482 mL	0.6205 mL
	50 mM	0.0199 mL	0.0993 mL	0.1986 mL	0.4964 mL
	60 mM	0.0165 mL	0.0827 mL	0.1655 mL	0.4137 mL
	80 mM	0.0124 mL	0.0621 mL	0.1241 mL	0.3103 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Oxytocin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Oxytocin50-56-6α-Hypophamine Oxytocic hormoneOxytocin ReceptorEndogenous MetaboliteOXTRhypothalamic peptidelactationprosocial behaviorsanti-inflammatoryantioxidantprotectivetraumaInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Oxytocin (Synonyms: α-Hypophamine; Oxytocic hormone)

Customer Review

Other Forms of Oxytocin:

Oxytocin Related Antibodies

24 Publications Citing Use of MCE Oxytocin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Oxytocin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report